[Anti-TNF-alpha chimeric antibody (infliximab)]

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Context:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and damage.
• Infliximab, a chimeric anti-TNF-alpha monoclonal antibody, has emerged as a significant therapeutic option for RA.
• Existing evidence demonstrates rapid symptom improvement and prevention of radiological progression in RA patients treated with infliximab.

Purpose:

• To evaluate the clinical utility of infliximab in managing rheumatoid arthritis.
• To assess the potential socioeconomic benefits of infliximab therapy, including maintaining employability.
• To determine the cost-effectiveness and long-term safety profile of infliximab for RA treatment in the Japanese population.

Summary:

• Infliximab treatment leads to rapid amelioration of clinical symptoms and signs in RA patients.
• Large clinical trials indicate that infliximab can prevent radiological progression and, in some instances, repair radiological damage.
• Early intervention with infliximab may halt bone erosions and prevent joint deformities in RA.
• Despite its high cost, infliximab may offer socioeconomic advantages by preserving patient employability compared to traditional disease-modifying antirheumatic drugs (DMARDs).

Impact:

• Early infliximab treatment could significantly alter the disease course of RA, preventing irreversible joint damage.
• Confirming the cost-effectiveness and long-term safety of infliximab is crucial for its optimal implementation in Japan.
• This research aims to provide essential data for healthcare providers and policymakers regarding infliximab's role in RA management.